CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

InfliximabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2777 chlorine dioxide 3000 ppm Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

We hypothesize that early institution of TNFα inhibitor therapy in patients with severe COVID-19 infections will prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality. To address this hypothesis, a prospective, single center, phase 2 trial is proposed to assess the efficacy of infliximab or infliximab-abda in hospitalized adult patients with severe or critical COVID-19. Observations from this study will inform the conduct of prospective randomized controlled studies to follow.

NCT04425538 COVID-19 Drug: Infliximab
MeSH:Coronavirus Infections

Primary Outcomes

Description: Time to improvement in oxygenation

Measure: Time to improvement in oxygenation

Time: 28 Days

Secondary Outcomes

Description: 28-day mortality

Measure: 28-day mortality

Time: 28 Days

Description: Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy

Measure: Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy

Time: 28 Days

Description: Qualitative and quantitative toxicity

Measure: Qualitative and quantitative toxicity

Time: 28 Days

Description: incidence and duration of supplemental oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device

Measure: incidence and duration of supplemental oxygen administration

Time: 28 Days

Description: Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula

Measure: Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula

Time: 28 Days

Description: Incidence and duration of mechanical ventilation

Measure: Incidence and duration of mechanical ventilation

Time: 28 Days

Description: Incidence and duration of vasopressor support

Measure: Incidence and duration of vasopressor support

Time: 28 Days

Description: Incidence and duration of extracorporeal membrane oxygenation

Measure: Incidence and duration of extracorporeal membrane oxygenation

Time: 28 Days

Description: Duration of fever

Measure: Duration of fever

Time: 28 Days

Description: Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives

Measure: Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives

Time: 28 Days

Description: Duration of hospitalization

Measure: Duration of hospitalization

Time: 28 Days

Description: Secondary infections

Measure: Secondary infections

Time: 28 Days

No related HPO nodes (Using clinical trials)